Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01167816 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
A Phase 1 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01167816 is a Phase 1 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 9 participants.
The verdict
NCT01167816, a Phase 1 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objective is to determine the maximum tolerated dose (MTD) of azacitidine and gemcitabine in subjects with previously untreated and unresectable pancreatic cancer. Also to determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells.
Interventions
- DRUG Vidaza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01167816
The ClinicalTrials.gov registry entry for NCT01167816 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vidaza is the first listed.
NCT01167816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01167816 about?
NCT01167816 is a clinical study titled "Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer". The primary objective is to determine the maximum tolerated dose (MTD) of azacitidine and gemcitabine in subjects with previously untreated and unresectable pancreatic cancer. Also to determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells.
What is the current status of trial NCT01167816?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-07. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01167816?
The interventions under investigation include: Vidaza (DRUG).
Who is sponsoring clinical trial NCT01167816?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.